| CAC1C_RAT |
Rattus norvegicus |
|
CAC1C_RAT is differentially expressed in 36 experiments [31 up/36 dn]: 19 organism parts: kidney [1 up/1 dn], peritoneal fat [0 up/1 dn], ...; 4 disease states: normal [0 up/1 dn], breast cancer [1 up/0 dn], ...; 6 cell types, 1 cell lines, 8 compound treatments and 7 other conditions. |
| CAC1C_RAT, Cach2, Cacn2, Cacnl1a1, rCG_29907, Cchl1a1, Cacna1c |
|
egl-19 (Caenorhabditis elegans)
CACNA1C (Homo sapiens)
Ca-alpha1D (Drosophila melanogaster)
Cacna1c (Mus musculus)
cacna1c (Danio rerio)
(Compare orthologs)
|
|
|
| Ion transport, Voltage-dependent calcium channel, L-type, alpha-1 subunit, Voltage-dependent calcium channel, L-type, alpha-1C subunit, Voltage-dependent calcium channel, alpha-1 subunit, IQ domain, Voltage-dependent calcium channel, alpha-1 subunit |
|
|
| adult walking behavior, calcium ion binding, calcium ion transport, calmodulin binding, cellular calcium ion homeostasis |
|
|
|
P22002
Q71QJ6
Q7TQ09
Q8VHT3
Q8VHT2
|
|
|
|
ENSRNOG00000007090
|
|
|
| Factor Value |
Factor |
Up/Down |
Legend: - number of studies the gene is up/down in
|
|
Kidney
|
Organism part |
|
|
Peritoneal fat
|
Organism part |
|
|
Tibialis anterior skeletal mus...
|
Organism part |
|
|
Extraocular skeletal muscle
|
Organism part |
|
|
Biological replicate 3
|
Replicate |
|
|
17a-ethynylestradiol
|
Compound treatment |
|
|
Genestein
|
Compound treatment |
|
|
P15
|
Developmental stage |
|
|
P30
|
Developmental stage |
|
|
Frontal cortex
|
Organism part |
|
|
Normal
|
Disease state |
|
|
Breast cancer
|
Disease state |
|
|
N-methyl-N-nitrosurea
|
Compound treatment |
|
|
Medial prefrontal cortex
|
Organism part |
|
|
Paraventricular nucleus
|
Organism part |
|
|
Spermatid
|
Cell type |
|
|
E16
|
Developmental stage |
|
|
Alveolar epithelial type II
|
Cell type |
|
|
Alveolar epithelial type I
|
Cell type |
|
|
E12.5
|
Developmental stage |
|
|
None
|
Clinical treatment |
|
|
Brain septum
|
Organism part |
|
|
P28
|
Developmental stage |
|
|
Dorsal striatum
|
Organism part |
|
|
Neurointermediate lobe
|
Organism part |
|
|
Endothelial cell
|
Organism part |
|
|
Liver
|
Organism part |
|
|
Proximal small intestine
|
Organism part |
|
|
Clofibrate
|
Compound treatment |
|
|
None
|
Injury |
|
|
Bone fracture
|
Injury |
|
|
Diethylhexylphthalate
|
Compound treatment |
|
|
Amygdala
|
Organism part |
|
|
P7
|
Developmental stage |
|
|
Spinal cord (T10)
|
Organism part |
|
|
Nucleus accumbens
|
Organism part |
|
|
None
|
Compound treatment |
|
|
Clofibric acid
|
Compound treatment |
|
|
Total_RNA
|
Material type |
|
|
Polysomal_RNA
|
Material type |
|
|
Moderate spinal cord injury
|
Disease state |
|
|
RI(BN-Lx/CubXSHR/Ola)
|
Strain or line |
|
|
Toxic compound
|
Clinical treatment |
|
|
Technical replicate 1
|
Replicate |
|
|
Mild spinal cord injury
|
Disease state |
|
|
Dorsal root ganglion
|
Organism part |
|
|
Cerebellum
|
Organism part |
|
|
Sprague Dawley
|
Strain or line |
|
|
BN-Lx
|
Strain or line |
|
|
Organism_part
|
Material type |
|
|
Cell
|
Material type |
|
|
SCN2.2
|
Cell line |
|
|
Instillation
|
Clinical treatment |
|
|
Inhalation
|
Clinical treatment |
|
|
Rat bone marrow conditioned me...
|
Growth condition |
|
|
Ventral striatum
|
Organism part |
|
|
Spermatogonium
|
Cell type |
|
|
Oligodendrocyte
|
Cell type |
|
|
Oligodendrocyte progenitor cel...
|
Cell type |
|
|
Fracture
|
Injury |
|
|
Intramedullary nail
|
Clinical treatment |
|
|
Bilateral disruption of the me...
|
Clinical treatment |
|
|
C85 tumor cell conditioned med...
|
Growth condition |
|
|
Cultured
|
Growth condition |
|
|
Freshly isolated
|
Growth condition |
|
|
LacZ
|
Compound treatment |
|
|
|
|
|
Processing time: 0.097 secs.